Login / Signup
In early Parkinson disease, daily subcutaneous lixisenatide reduced motor disability progression at 12 mo.
Joseph H Friedman
Published in:
Annals of internal medicine (2024)
N Engl J Med. 2024;390:1176-1185. 38598572.
Keyphrases
</>
parkinson disease
deep brain stimulation
multiple sclerosis
physical activity